Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...
Jasper Therapeutics, Inc. (($JSPR)) announced an update on their ongoing clinical study. Jasper Therapeutics, Inc. is conducting a clinical study ...
“Dosing of the first patient in our ETESIAN study in asthma is a significant milestone, marking our third clinical program evaluating briquilimab in an inflammatory disease driven by unwanted mast ...
Jasper Therapeutics, Inc. announced promising results from its BEACON Phase 1b/2a study of briquilimab, an antibody therapy targeting mast cell diseases like chronic spontaneous urticaria (CSU). In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback